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Abstract: Gene associated with retinoid-interferon-β-induced mortality (GRIM)—19, was originally identiﬁ  ed as a critical 
regulatory protein necessary for Interferon-β-Retinoic acid-induced cell death. Overexpression of GRIM-19 activates cell 
death and its suppression or inactivation promotes cell growth. GRIM-19 targets multiple proteins/pathways for exerting 
growth control and cell death. However, GRIM-19 is also required for normal cellular processes. In addition, viruses ‘hijack’ 
GRIM-19 for their survival. Intracellular bacterial infections and bacterial products have been reported to induce the expression 
of GRIM-19. In this review, we will discuss the current status of GRIM-19 in growth control and innate immune response.
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Introduction
In multicellular organisms, temporal and spatial control of gene expression and gene products are very 
crucial for maintaining tissue homeostasis (Evan and Vousden, 2001). This balance comes essentially 
from the stochiometric and functional level(s) of various gene products that are involved in a process 
or/and necessary for such a cross talk. Any tilt in this delicately balanced process results in an abnormal 
cellular experience such as stress; and the cellular machinery tries to restore it to normalcy. Hence, 
higher order organisms have evolved multiple stress-sensing, alerting and relieving systems that are 
beneﬁ  cial for organismal homeostasis. Cytokines are small-secreted proteins with multiple functions 
whose optimal responses are beneﬁ  cial (Evan and Vousden, 2001). In this review, we will focus on a 
speciﬁ  c cytokine-induced novel growth-suppressor and its mechanisms of action.
Pathways of Apoptosis
Apoptosis, a naturally-occurring programmed cell suicide mechanism, enables metazoans to control 
cell numbers in tissues; and eliminates cells that threaten the organism’s survival in an orderly manner 
(Kerr et al. 1994). There are at least two broad pathways that lead to apoptosis viz., extrinsic and intrin-
sic. In both pathways, signaling results in the activation of a family of cysteine proteases, named Cas-
pases, which act in a orchestrated proteolytic machinery to dismantle the cell architecture (Czerski and 
Nunez, 2004). In the extrinsic pathway, extra-cellular protein(s) trigger the apoptotic response, while 
in the intrinsic pathway intra-cellular factor(s) elicit the apoptotic response. The extrinsic pathway 
depends on cell surface receptor systems and the intrinsic pathway is activated by oncogenes, DNA 
damage, hypoxia, mitochondrial damage etc.
Receptor-mediated apoptosis involves speciﬁ  c ligand-receptor interactions that transduce signals which 
culminate in the activation of distinct Caspases. Eight such death receptors (DRs) have been characterized 
so far: DR1 (also known as TNFR1, CD120a, p55 and p60) (Sutheesophon et al. 2005), DR2 (also known 
as FasR, APO1 and CD95) (Jung and Kim, 2004), DR3 (also known as APO3, LARD, TRAMP and 
WSL1) (Shi et al. 2003), DR4 (also known as APO2, TRAILR1) (Kaufmann and Steensma, 2005; Luschen 
et al. 2005), DR5 (also known as TRAILR2, KILLER and TRICK2) (Kaufmann and Steensma, 2005; 
Luschen et al. 2005), DR6 (Shi et al. 2003), EDAR (Ectodysplasin-A Receptor) and NGFR (Nerve Growth 
Factor Receptor) (Wajant, 2003). These receptors are distinguished by a cytoplasmic region, of approximately 68
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80 amino acid residues, termed the death domain 
(DD). Upon activation, a number of proteins are 
recruited to the DD and subsequently a signaling 
cascade is activated. Two such DR-signaling com-
plexes can be distinguished: the 1
st group composed 
of the DISCs (Death-Inducing Signaling Com-
plexes) that are formed with DR2, DR4 and DR5 
have similar composition and the 2
nd group com-
posed of TNFR1, DR3, DR6 and EDAR that have 
different set of molecules which transduce the signal 
leading to activation of the initiator Caspase (pro-
Caspase8 to Caspase8 through self-cleavage) which 
activates down-stream Caspases. However, the lat-
ter group is known to transduce survival signals (Fas 
et al. 2006; Sandu et al. 2005).
In addition to receptor-mediated apoptosis, there 
is another pathway activated by various forms of 
cytotoxic stress-inducers like γ–rays, uv-rays, 
drugs like Actinomycin-D, removal of cytokines 
etc that involves altering the mitochondrial perme-
ability transition (Harris and Levine, 2005) and 
subsequent release of cytochrome-c and formation 
of the Apoptosome, a catalytic multi-protein plat-
form that activates Caspase9, which in turn acti-
vates Caspase3 leading to the later events involved 
in cell death (Pirnia et al. 2002).
The intrinsic pathway is activated when an 
injury occurs within a cell such as DNA damage, 
hypoxia etc. The p53 protein is a sensor of cellular 
stress and is a critical activator of the intrinsic 
pathway (Haupt et al. 2003). Activated p53 initiates 
apoptosis by activating pro-apoptotic Bcl-2 family 
members while repressing the expression of anti-
apoptotic Bcl-2 members and cellular inhibitors of 
apoptosis proteins (CIAPs). Other p53 targets 
include BAX, Noxa, PUMA, BID and genes which 
cause an increase in ROS (reactive oxygen species) 
and damage mitochondrial components (Uren et al. 
2005).
Most of the above pathways culminate in the 
activation of Caspase-activated DNAse (CAD) 
(Uren et al. 2005), generation of pro-apoptotic 
peptides from the Bcl-2, Bcl-XL, Bid proteins. 
Although many death signals employ at least one 
of these pathways in later stages of cell death, their 
upstream factors are quite often different.
Interferon Signaling in Growth 
Control
Interferons (IFNs) are critical regulators of 
anti-viral, anti-microbial, anti-tumor, cellular 
differentiation and immune response activities 
(Boehm et al. 1997; Kalvakolanu, 2000; Sen, 
2000). The primary IFN-signaling is routed through 
the JAK-STAT pathway (Levy and Darnell, 2002; 
Stark et al. 1998) and the biological responses of 
IFNs is controlled by two classes of transcription 
factors viz., Interferon-gene Regulatory Factors 
(IRFs) and STATs (Fujita et al. 1989; Pine et al. 
1990). The former regulate IFN genes and some 
ISGs while the latter primarily regulate ISGs. 
These factors cross-regulate each other and form 
complexes with other factors to deliver distinct 
biological response(s) based on recruitment to dif-
ferent promoter elements. The Interferon-
Stimulated Response Element (ISRE) is one such 
element where a multimeric transcription factor 
(ISGF3) comprising of IRF9, STAT1 and STAT2 
binds and drives transcription of certain ISGs 
(Levy and Darnell, 2002; Stark et al. 1998). In a 
similar manner, binding of activated STAT1 fol-
lowing IFN-γ treatment drives transcription of 
some ISGs that possess a Gamma-Activated Sites 
(GAS) element in their promoter (Shuai et al. 1994; 
Shuai et al. 1992). Cytokine-induced STAT-driven 
responses are controlled by feedback mechanisms 
that control the time/extent/ampliﬁ  cation from the 
initial signaling event. The first mechanism 
involves phosphatases that dephosphorylate active 
STAT proteins e.g. dephosphorylation of STAT1 
and STAT5 by the phosphatase TcPTP (Aoki and 
Matsuda, 2002; ten Hoeve et al. 2002). The second 
mechanism involves inhibitors that bind to acti-
vated STAT proteins, which prevent their DNA 
binding e.g. the binding of PIAS1 to STAT1 
(Chung et al. 1997; Liu et al. 1998). The third 
mechanism involves STAT-induced factors called 
Suppressor of Cytokine Signaling (SOCS) proteins 
that bind to the JAKs and inhibit their activity e.g. 
SOCS3 against STAT3 (Hanada et al. 2003; 
Karlsen et al. 2001; Morita et al. 2000; Starr and 
Hilton, 1999). Multiple SOCS proteins have been 
described that target distinct JAKs (Alexander et al. 
1999; Croker et al. 2003).
IFNs were the ﬁ  rst cytokine therapeutics used 
clinically for the therapy of many viral diseases, 
malignancies or syndromes (Borden et al. 2000). 
As expected, IFNs, IFN receptors and the tran-
scription factors regulated by them play important 
roles in eliminating neoplastic growth (Gresser 
and Belardelli, 2002; Ikeda et al. 2002). For exam-
ple, mutations in the human IRF1 gene has been 
linked to myeloid leukemia (Willman et al. 1993); 69
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deletion of the IRF8 gene causes a CML-like 
disease in mice (Holtschke et al. 1996), while in 
humans expression of IRF8 was depressed 
(Schmidt et al. 1998), and in CML patients having 
the BCR-ABL oncogene re-expression of IRF8 
suppressed the myelo-proliferative disorder (Hao 
and Ren, 2000). The IFN-γ receptor
−/− and 
STAT1
−/− mice are highly susceptible to chemical 
carcinogenesis (Kaplan et al. 1998). Although a 
great deal is known about anti-viral actions of 
IFNs, their anti-tumor actions are not fully under-
stood. The anti-tumor activity of IFNs as a single 
agent is comparable to that of many therapeutics. 
In some cases, insensitivity to IFN-induced anti-
tumor effects could be overcome by combining 
with other agents such as the cell differentiating 
agents, retinoids.
Retinoid Signaling in Growth 
Control
Retinoids are a group of Vitamin-A-related com-
pounds that regulate cell growth, differentiation 
and embryogenesis in vertebrates (Love and 
Gudas, 1994). All trans retinoic acid (ATRA or 
RA), a closest metabolite of Vitamin A, can drive 
all functions except vision (Love and Gudas, 1994). 
The importance of retinoids in growth regulation 
is highlighted by a higher incidence of cancers in 
animals deprived of Vitamin A that can be reversed 
or controlled by RA treatment (Bjelke, 1975; 
Kuwata et al. 2000). The biological actions of 
retinoids are exerted via two structurally similar, 
but genetically distinct, nuclear retinoid receptors 
viz., Retinoic Acid Receptors (RARs) and Retinoid 
X Receptors (RXRs) that are constitutively bound 
to speciﬁ  c DNA sequence motifs known as the 
Retinoic Acid Response Elements (RARE), as 
heterodimers (Chambon, 1996; Kliewer et al. 1992; 
Mangelsdorf and Evans, 1995; Nagpal et al. 1992). 
A number of isotypes of RARs and RXRs (α, β 
and γ) and their subtypes participate in retinoid-
induced transcription. Most RAR and RXR genes 
are constitutively expressed except for the RARβ 
gene whose expression is up-regulated by RA-
treatment (Chambon, 1996; Mangelsdorf and 
Evans, 1995). Mutations in the RAR and RXR 
genes occur rarely. The expression of RARβ gene 
is inhibited in some cancers and its re-expression 
restores growth arrest in response to RA (Liu 
et al. 1996). Indeed transgenic mice expressing 
anti-sense RARβ gene develop lung cancers; 
although the exact mechanism(s) are unknown 
(Berard et al. 1996). The only well-deﬁ  ned muta-
tion that involves RARs is a reciprocal transloca-
tion that occurs between the RARα (human 
chromosome 17) and the promyelocytic leukemia 
(human chromosome 15) loci in some forms of 
acute promyelocytic leukemia (APL) (de The et al. 
1991; Kakizuka et al. 1991). Despite this transloca-
tion, PML-RARα protein responds to RA treatment 
and leukemic cell growth is successfully controlled 
in APL patients (Chomienne et al. 1990; Hofmann, 
1992). The PML gene is induced by IFNs via 
STAT1-dependent pathway and implicated in the 
anti-viral actions of IFNs (Pelicano et al. 1997; 
Regad et al. 2001).
Crosstalk Between IFNs 
and Retinoids
Although IFNs and retinoids induce genes using 
different signaling pathways, several studies have 
shown that a crosstalk exists between their growth-
suppressive pathways (Chelbi-Alix et al. 1998; 
Nason-Burchenal et al. 1996; Ruggero et al. 2000). 
For example, RA-induced expression of STAT1 
augments IFN-induced responses while a mutant 
STAT1 inhibits RA-induced differentiation 
(Dimberg et al. 2000; Gianni et al. 1997; Kolla et 
al. 1997; Matikainen et al. 1997). Experimental 
and clinical models have shown that IFN-RA com-
bination synergistically inhibits tumor growth and 
tumor angiogenesis compared to either agent alone 
(Frey et al. 1991; Hemmi and Breitman, 1987; 
Lindner et al. 1997; Marth et al. 1986). Further-
more, apoptosis occurred in cells that lacked either 
a functional p53 or/and Caspase3 implying the 
factors are distinct from known death regulators. 
Using a genetic screen, our lab isolated the medi-
ators of the growth-suppressive effect of IFN/RA. 
These were collectively called the GRIMs (Genes 
associated with Retinoid-Interferon-induced 
Mortality).
Isolation of the GRIMs
The use of genetic approaches to identify genes 
based on their function will rapidly advance our 
understanding of cellular processes. Employing an 
anti-sense technical knockout strategy (Deiss and 
Kimchi, 1991), we isolated genes that regulate cell 
death in response to IFN/RA treatment (Hofmann 
et al. 1998). Brieﬂ  y, total RNA prepared from 
untreated and IFN/RA-treated cells (multiple time 70
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points) were pooled and a cDNA library was 
constructed. This unampliﬁ  ed cDNA library was 
cloned into an episomal vector pTKO1 to generate 
an anti-sense library. When transfected into cells 
and selection pressure applied with IFN/RA, cells 
that harbor an anti-sense against a death-associated 
gene transcript will selectively survive in the pres-
ence of IFN/RA. Individual episomes were rescued 
from the surviving colonies and tested for protec-
tion against IFN/RA-induced cell death to elimi-
nate false positives. Episomes that consistently 
conferred protection against IFN/RA-induced cell 
death were collectively called the GRIMs. Partial 
sequences have revealed that most of these genes 
were novel. Isolation of several GRIMs using this 
approach suggests the existence of a coordinated 
network of factors that are necessary for executing 
IFN/RA-induced cell death. Consequently, inter-
fering with one gene product is sufﬁ  cient to abolish 
cell death. In this review, we will focus on 
GRIM-19, which has emerged as a key player in 
growth control and apoptosis using in-vitro and 
in-vivo models.
GRIM-19—An Introduction
In humans, the gene for GRIM-19 maps to a locus 
on chromosome 19 (Chidambaram et al. 2000), 
whose loss has been implicated in prostate cancer 
progression (Gao et al. 1999). The gene is 
∼13.0 Kb and consists of 5 exons. Other salient 
features of this gene are: a) extremely GC-rich, 
b) the ﬁ  rst intron is very long ∼9.0 kbp, c) minimal 
5’ and 3’ UTRs. The protein encoded by this gene 
has a mass of ∼16 kDa with no apparent sequence-
motif or domain identities with other proteins in 
the databases. Immunohistochemical studies 
revealed that GRIM-19 is distributed in the 
cytoplasm and nucleus as punctate structures 
indicative of its presence in certain protein 
complexes in-vivo (Angell et al. 2000). Indeed, a 
subsequent study reported GRIM-19 to be a part 
of purified Complex-I of the mitochondrial 
electron transport system (ETS) that generates 
the electro-chemical gradient required for ATP 
synthesis (Fearnley et al. 2001; Murray et al. 
2003). This characteristic may indicate as to why 
a homozygous deletion results in embryonic 
lethality in mice. However, studies that are more 
detailed are required for deciphering the actual 
role of GRIM-19 in steady-state. Ectopic expression 
of GRIM-19 induces cell death and moderate 
levels of it sensitizes cells to IFN/RA-induced 
apoptosis (Angell et al. 2000).
Viruses Target GRIM-19 
for Cell Survival
The initial anti-GRIM-19 activities came from 
studies on human Herpesvirus-8 (HHV-8) that is 
frequently associated with Kaposi’s sarcoma (KS), 
B-cell Lymphoma (BCL), multicentric castleman 
disease (MCD) and primary effusion lymphoma 
(PEL) (Gillison and Ambinder, 1997; Neipel and 
Fleckenstein, 1999). The viral genome, in addition 
to several structural proteins, also codes for a 
number of proteins homologous to various cellular 
proteins viz., viral IL-6 (vIL-6), viral Bcl2 (vBcl2), 
and three viral homologues of IRFs (vIRFs) etc. 
The viral IRFs (vIRFs) are implicated in cellular 
transformation and also function as arsenals to 
counter the host response against invading patho-
gen (Burysek and Pitha, 2001; Moore et al. 1996). 
The vIRF1 protein inhibits IFN-gene expression 
by interfering with the interaction of CBP/p300 
with co-activator, IRF3 (Burysek et al. 1999; Li 
et al. 2000; Lin et al. 2001). It does not bind to 
DNA like IRFs. We have shown that vIRF1 binds 
with GRIM-19 and blocks its ability to induce 
apoptosis (Seo et al. 2002). However, vIRF1 also 
activates the expression of growth promoting tran-
scription factor c-Myc (Jayachandra et al. 1999). 
The vIRF2 protein inhibits protein kinase R (PKR), 
a translation-inhibitory kinase induced by type-I 
IFNs and double-stranded RNA, that phosphory-
lates translation initiation factor (eIF2α) leading 
to inhibition of protein synthesis (Burysek and 
Pitha, 2001). The human Papillomavirus (HPV) 
E6 protein of the high-risk strains, but not the low-
risk strains, binds to GRIM-19 (Seo et al. 2002). 
Other viruses appear to target GRIM-19 using dif-
ferent mechanisms. For example, upon Vaccinia 
virus (VV) infection, de-novo levels of GRIM-19 
dropped signiﬁ  cantly at 2 h post-infection and 
maintained at low level as long as 16 hours post-
infection (Guerra et al. 2003). The factors/mecha-
nisms involved in this process are not identiﬁ  ed. 
A more provoking mechanism is employed by 
human Cytomegalovirus (CMV). The viral genome 
encodes a highly abundant 2.7-kb RNA transcript 
(β2.7) that accounts for 20% of total viral transcrip-
tion (Greenaway and Wilkinson, 1987; Spector, 
1996) of unknown function and no protein product 
has been detected in infected cells suggesting that 71
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it may function as a non-coding RNA (McSharry 
et al. 2003). The virus employs this RNA to ‘lock-
up’ GRIM-19 in Complex-I, hence renders it inef-
fective in triggering the apoptotic cascade (Reeves 
et al. 2007).   A viral mutant, lacking β2.7, was 
ineffective at preventing apoptosis upon infection. 
The functionality of β2.7 did not change when 
provided in trans i.e. in an expression vector, 
suggesting its independence from other viral 
proteins. Inspite of the virus up-regulating steady-
state levels of mRNAs coding for some subunit 
proteins in the Complexes-I to V, GRIM-19 levels 
were unaffected as long as 120 hours post-infection 
(Reeves et al. 2007). Why and how the virus 
achieves this state is worth investigating. Reeves 
et al. (2007) also suggested that localization of 
GRIM-19 is not constant and can change according 
to the need of the cell, which may explain the 
disparity among research groups about the localiza-
tion of GRIM-19 (more in later sections).
Cellular Targets of GRIM-19
To gain a better understanding of GRIM-19-induced 
growth suppression, we had used yeast two-hybrid 
(Y2H) screen to identify the cellular targets. Initial 
studies identiﬁ  ed STAT3 as one of its interacting 
partners (Lufei et al. 2003; Zhang et al. 2003). 
STAT3 is central to several diverse biological func-
tions in mammals including cytokine-driven 
responses, differentiation, embryonic growth and 
cell survival (Akira et al. 1994; Bowman et al. 
2000; Zhong et al. 1994). In normal cells, STAT3 
activity is tightly regulated by feedback inhibitory 
mechanisms that prevent excessive signaling. 
Constitutive activation of STAT3 has been docu-
mented in many tumors and it inhibits apoptosis 
(Bowman et al. 2000; Bromberg, 2001; Cattaneo 
et al. 1998; Garcia et al. 1997; Gouilleux-Gruart 
et al. 1996; Schrell et al. 1998). Interference with 
STAT3 function promotes apoptosis (Catlett-
Falcone et al. 1999; Epling-Burnette et al. 2001; 
Gao et al. 2005; Grandis et al. 2000; Nielsen et al. 
1999; Niu et al. 2001). Interestingly, GRIM-19 
interferes with STAT3 distinctly and does not fall 
into the known categories of cytokine-induced 
feedback regulatory mechanisms. Our results have 
indicated that GRIM-19 binds to the trans-
activating domain (TAD) of STAT3 and blocks its 
activity. Lufei et al. (2003) reported that GRIM-19 
binds to the coiled-coil, DNA-binding and linker 
domains of STAT3. This study mainly used 
overexpression strategy. In contrast, our results 
were inferred using point mutations in the TAD 
and STAT3 truncations in a stat3
−/− background. 
We have also shown that TAD alone is insufﬁ  cient 
for GRIM-19 binding suggesting an additional site 
or/and factor(s) mediating this interaction (Zhang 
et al. 2003). Lastly, we have recently reported the 
effects of GRIM-19 binding to a constitutively 
active form of stat3 (S3C) (Kalakonda et al. 
2007b). S3C protein has been engineered to behave 
like phosphorylated-STAT3 i.e. spontaneous 
homo-dimer formation, that localizes it to the 
nucleus (Bromberg et al. 1999). By Western 
analyses, we have shown S3C-GRIM-19 com-
plexes in the nuclear extracts, which is contrary to 
the mechanism suggested by Lufei et al. (2003) 
i.e. GRIM-19 functioned only to block the nuclear 
entry of activated STAT3. Additionally, binding of 
GRIM-19 to STAT3 or S3C did not prevent the 
DNA-binding of STAT3 or S3C as revealed by 
ChIP analysis of STAT3-responsive gene promot-
ers, which again is contradictory to the mechanism 
suggested by Lufei et al. (2003) wherein GRIM-19 
blocked the DNA-binding ability of STAT3 by 
steric hindrance to its DNA-binding domain. It 
should be noted that Lufei et al.’s (2003) conclu-
sions were entirely drawn on the basis of overex-
pression of STAT3 and GRIM-19 in COS cells. It 
is likely that overexpression-associated artifacts 
may explain the hindrance of nuclear translocation 
of STAT3. Despite these differences with respect 
to localization of GRIM-19, mechanism of action, 
intra-cellular environment of complex formation 
etc, all studies agree on the death-inducing potential 
of GRIM-19 and its anti-STAT3 effects. Is anti-
STAT3 activity just sufﬁ  cient to block cell prolif-
eration vis-à-vis tumor growth in all scenarios? Our 
recent studies have shown that interference with 
STAT3 function either by direct blockade of STAT3 
expression, by intratumoral administration of 
shRNA expression vectors (Zhang et al. 2007) or 
by intratumoral expression of GRIM-19 (Zhang 
et al. Clin Cancer Res, In press) is one major 
mechanism of tumor growth suppression in vivo.
Another group reported a growth-promoting 
gene product that interacts with GRIM-19 using 
Y2H screen (Zhang et al. 2004). This gene, gw112, 
bears little homology to other known genes and is 
highly expressed in the tumors of the gastro-intes-
tinal tract. Immunochemical analysis revealed that 
most of GW112 protein to be in mitochondria and 
some in the nucleus as distinctive foci. Levels of 72
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GW112 were very high during early S-phase that 
gradually declined over late S-phase and was 
required for G2/M transition (Kobayashi et al. 
2007). However, reduction of GW112 levels by 
siRNA-based strategy resulted only in a slight 
increase in apoptosis, which is drastically different 
compared with STAT3 interference. Overexpres-
sion of GW112 can attenuate H2O2 and IFN/RA-
induced apoptosis (Kobayashi et al. 2007). 
Although the exact function and growth-promoting 
mechanism of GW112 is not clear, three genes 
products involved in apoptosis and oxidative-stress 
(PIG12, GADD153 and c-Abl) were down-
regulated in GW112-overexpressing cells, while 
the same genes were up-regulated in GRIM-19-
overexpressing cells or/and in response to IFN/RA 
treatment (Kobayashi et al. 2007).
Barnich et al. (2005) identiﬁ  ed NOD2 (nucleo-
tide-binding oligomerization domain containing 
2) as an interacting partner of GRIM-19 in another 
Y2H screen. NOD proteins are a group of intra-
cellular bacterial molecular pattern-recognition 
sensors that are thought to utilize RIP2/RICK and 
induce NF-κ B activation. Together with cell mem-
brane-associated TLRs (Toll-Like Receptors), 
NOD proteins play important roles in innate and 
acquired immunity. However, the study found 
GRIM-19 to be crucial for NF-κB activation fol-
lowing NOD2-mediated recognition of bacterial 
muramyl dipeptide. GRIM-19 appeared to be a key 
component in NOD2-mediated innate mucosal 
responses. Interestingly, GRIM-19 localized in 
vesicles, which are not near the cell membrane, 
not in mitochondria or the nucleus in this study 
whose signiﬁ  cance needs to be addressed. Barnich 
et al. (2005) also reported up-regulation of GRIM-
19 when challenged by intra-cellular bacteria.
One of the recent GRIM-19 binding partners is 
HtrA2, a serine protease localized in the mitochon-
dria (Ma et al. 2007). In mammalian cells, inhibi-
tors of apoptosis proteins (IAP) block Caspase 
activation. One such protein, X-linked IAP (XIAP) 
inhibits Caspase9. HtrA2 degrades XIAP to relieve 
the inhibition on Caspases. Upon IFN/RA treat-
ment, HtrA2 and GRIM-19 are released from 
mitochondria and they form a complex in the cyto-
sol that degrades XIAP. The interaction between 
GRIM-19 and HtrA2 was signiﬁ  cantly stronger 
upon IFN/RA treatment suggesting some post-
translational change(s) that increases the binding 
potential (Ma et al. 2007). Indeed, a recent study 
reported dynamic phosphorylation of Threonine 
113 of GRIM-19 in steady-state (Palmisano et al. 
2007). Interestingly, one of the GRIM-19 point 
mutations, (Arginine 115 Proline) reported in the 
thyroid cancer (Maximo et al. 2005), is in close 
vicinity to the phosphorylation site. Whether such 
phosphorylation has any biological relevance needs 
to be experimentally deﬁ  ned. These in conjunction 
with our earlier ﬁ  nding that the deletion of the 
C-terminus of GRIM-19 abrogates its death-
promoting function (Angell et al. 2000) appear to 
be relevant in this context while the full spectrum 
of changes that should occur to GRIM-19 for it to 
induce apoptosis cannot be addressed at present.
Our latest report addressed the src-family of 
tyrosine kinases, which are important regulators 
of various cell growth responses viz., cellular 
transformation, altering transcription, cytoskeletal 
properties (Behrens et al. 1993; Frame, 2004; 
Frame et al. 2002; Lin et al. 1983; Perucho and 
Esteban, 1985) etc. Since STAT3 and Src both are 
pro-growth genes and having studied the effect of 
GRIM-19 on STAT3, we addressed the role of 
GRIM-19 on Src. GRIM-19 suppressed Src-
induced cellular transformation in vitro and in vivo 
by down-regulating the expression of a number of 
STAT3-responsive genes (Kalakonda et al. 2007a). 
In addition, GRIM-19 inhibited the Src-induced 
cell motility and metastasis by suppressing the 
tyrosyl-phosphorylation of focal adhesion kinase 
(FAK), paxillin, E-cadherin and gamma-catenin. 
The effects of GRIM-19 on Src-induced cellular 
transformation were reversible in the presence of 
GRIM-19-speciﬁ  c short hairpin RNA, indicating 
its direct effect on transformation. GRIM-19-
mediated inhibition of the Src-induced tyrosyl 
phosphorylation of cellular proteins, such as FAK 
and paxillin, seemed to occur independently of the 
STAT3 protein. GRIM-19 had no signiﬁ  cant effect 
on the cellular transformation induced by other 
oncogenes such as myc and Ha-ras (Kalakonda 
et al. 2007a). Thus, GRIM-19 not only blocked 
Src-induced gene expression through STAT3 but 
also the activation of cell adhesion and motility-
related molecules. Similar effect on cell motility 
is controlled by another protein Stathmin that 
destabilizes microtubules (Ng et al. 2006). STAT3 
interacted with Stathmin thus antagonizing its 
destabilizing activity. Since GRIM-19 interacts 
with STAT3, these inhibitory networks may be 
operative in parallel.
Another interesting report concerns the role of 
Janus tyrosine kinase, Tyk2, in mitochondrial 73
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respiration in primary pro-B lymphocytes in a 
mouse model (Potla et al. 2006). Although tyk2
−/− 
mice were phenotypically normal, cells from 
such mice exhibited abnormal responses to inﬂ  am-
matory challenges in different cell types; speciﬁ  -
cally pro-B cells were markedly deﬁ  cient in basal 
oxygen consumption and exhibited a signiﬁ  cant 
decrease in steady-state cellular ATP levels which 
were attributed to impaired complex-I, complex-
III and complex-IV functions of the mitochondrial 
ETS. However, Tyk2 was required for mainte-
nance of both complex-I-dependent respiration as 
well as induction of apoptosis in cells incubated 
with IFN-β. Consistent with the role of Tyk2 in 
the regulation of tyrosyl-phosphorylation of 
STAT3, expression of constitutively active STAT3 
(S3C) could restore the mitochondrial respiration 
and IFN-β-stimulated apoptosis in Tyk2
−/− cells 
treated with IFN-β. Though S3C did restore IFN-
β-stimulated apoptosis, it was incomplete suggest-
ing another Tyk2-dependent pathway is necessary 
for the full response. This appears to be an enigma 
wherein STAT3 phosphorylation stabilizes com-
plex-I respiration, Tyk2 and phosphorylated 
STAT3 are required for apoptosis, the same JAK-
STAT pathway induces GRIM-19 while the recep-
tor stimulation causes GRIM-19 release from 
complex-I. It is debatable as to which route of 
signaling is stronger to achieve the outcome i.e. 
survival/apoptosis. These results could also be 
interpreted as a novel mechanism to control 
STAT3 activity wherein, GRIM-19 from some of 
the complex-I gets released to bind STAT3 and 
control the temporal or/and spatial activity of 
STAT3 in the nucleus. However, novel roles for 
non-phosphorylated STAT3 have been reported 
(Yang et al. 2005) suggesting other factors or/and 
promoter-context may also be important. More 
importantly, the generality of this observation to 
other cell types, other than pro-B cells, needs to 
be veriﬁ  ed.
Inducers of GRIM-19
As mentioned above, coupling of TLR4 and NOD2 
signals is necessary for innate immunity. Does 
activation of cell membrane-associated TLRs 
result in an up-regulation of GRIM-19? When 
CaCo2 cells were challenged with Salmonella 
typhimurium, grim-19 mRNA levels were 2.26-
fold higher, within 2 hours, than control cells 
whilst a challenge with non-pathogenic E. coli did 
not induce the mRNA levels signiﬁ  cantly (Barnich 
et al. 2005). Similarly, BCG-CWS up-regulated 
GRIM-19 levels in monocytes and DCs prepared 
from peripheral blood (Begum et al. 2004) whereas 
only a live periodontal pathogen (Porphyromonas 
gingivalis) could up-regulate GRIM-19 levels, 
neither its LPS nor its ﬁ  mbrial proteins, in periph-
eral blood monocytes (Zhou and Amar, 2006). The 
kinetics of GRIM-19 up-regulation in CaCo2 cells 
is very rapid compared to stimulation by BCG-
CWS or P. gingivalis or IFN/RA. Eventhough this 
variability could be a cell-speciﬁ  c effect or the 
speciﬁ  city of Ligand-TLR interaction, the mech-
anism or/and pathways involved merits investiga-
tion. On closer examination, one may interpret 
these results as: 1) the actual cells that encounter 
the pathogen i.e. natural route of entry, can up-
regulate apoptotic machinery very rapidly to 
control the infection; 2) cells of the immune sys-
tem have some time-lag in up-regulating GRIM-
19; and 3) a signal from the initial event invokes 
cells of the immune system to respond to this 
signal and up-regulate other defense mechanisms, 
one of which involves GRIM-19. Although there 
are reports of E. coli LPS being more potent than, 
P. gingivalis LPS, the latter has been known to 
modulate the host response to facilitate coloniza-
tion (Agarwal et al. 1995; Darveau et al. 2002; 
Murray and Wilton, 2003; Reife et al. 1995), while 
E. coli being a common intestinal ﬂ  ora is not rec-
ognized as a pathogen by the intestinal cells or 
cell line. In an analogous system, differential-
response and enrichment of GRIM-19 ESTs was 
observed in hemocytes from mosquitoes, Armi-
geres subalbatus and Aedes aegypti, challenged 
with E. coli and Micrococcus luteus (Bartholomay 
et al. 2004).
Patho-Physiological Relevance 
of GRIM-19
In this section, we will discuss the role of GRIM-19 
in different pathogenic processes. Chronic Obstruc-
tive Pulmonary Disease (COPD) is a collective 
term for describing two distinct lung diseases: 
emphysema and chronic bronchitis, caused by 
cigarette smoking (Petty, 2002) that accounts for 
80%–90% of COPD cases in the United States 
(Sethi and Rochester, 2000). However, only 
15%–20% of heavy smokers develop clinically 
signiﬁ  cant airﬂ  ow obstruction, which suggests a 
genotypic influence in disease development. 74
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The genes that determine susceptibility through 
disease progression are poorly understood (Mayer 
and Newman, 2001). Employing SAGE, Microar-
rays and qRT-PCR, (Ning et al. 2004) showed that 
grim-19 mRNA levels were higher in smoker’s 
lung compared to non-smokers, in addition to 
cdkn1a and cdc2l1. However, mitochondrial ETS 
complex-I activity was reduced by 50%.
Apoptosis-inducing factor (AIF) is a mito-
chondrial ﬂ  avoprotein that, after apoptosis induc-
tion, translocates to the nucleus where it 
participates in apoptotic chromatinolysis (Susin 
et al. 1999; Ye et al. 2002; Yu et al. 2002). The 
physiological role of AIF in the mitochondria is 
not clear at this stage. Though AIF is not a part 
of sub-complexes of complex-I or mature 
complex-I or any super-complexes, it is required 
for proper assembly and/or maintenance of respi-
ratory chain complex-I. AIF knockdown resulted 
in decreased GRIM-19 (NDUFA13), NDUFB6, 
NDUFS7 and NDUFA9 levels, all of which are 
parts of complex-I (Vahsen et al. 2004). However, 
AIF
−/− cells still had complete complex-I but in 
reduced abundance resulting in lower enzymatic 
activities and metabolized glucose like cancer 
cells.
In a study of patients with inﬂ  ammatory bowel 
disease (IBD) viz., Crohn disease (CD) and Ulcer-
ative Colitis (UC), Barnich et al. (2005) showed 
signiﬁ  cantly lower abundance of GRIM-19 in the 
involved areas compared to the non-involved areas 
of the intestinal mucosa. The mechanism(s) of such 
down-regulation is/are not known. This may be a 
very good working model for accessing the role of 
GRIM-19 in the development of neoplasia and 
metastasis.
In a very recent collaborative study we have 
shown that, focal cerebral ischemia up-regulated 
GRIM-19 levels signiﬁ  cantly in the affected areas 
of the brain in a rat model. Upon treatment of 
neuroblastoma cell line with IFN/RA for 48 h, 
GRIM-19 levels were up by ∼15-fold, while focal 
ischemia for 24 h could up-regulate grim-19 
mRNA ∼32-fold but only 50% increase in protein 
level (Mehrabian et al. 2007). This discordance 
between protein and RNA levels could be due to 
an inhibition of protein synthesis in ischemically 
damaged cells. However, a cell-speciﬁ  c effect was 
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Figure 1. Viral Inhibitors of GRIM-19. Viruses effectively block GRIM-19’s action either by preventing its release from mitochondria and/or 
its action by sequestering with viral gene products. Lines in Red indicate blockade of GRIM-19 action involving the indicated viral components. 
Lines in Green indicate transcriptional repression. Mechanism of transcriptional repression is not known.75
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also evident with respect to grim-19 induction by 
hypoxia; the ipsilateral lobes had higher GRIM-19 
levels compared to the contralateral lobes and the 
neurons had higher GRIM-19 levels compared to 
astrocytes.
GRIM-19 and Cancer
The full development of cancer involves multiple 
genetic changes that occur in a tumor-speciﬁ  c 
manner. Mutations/repression/loss of genes coding 
for transcription factors and apoptotic machinery 
have been implicated in tumor growth. As men-
tioned earlier, viruses and other cellular factors 
bind to GRIM-19 and prevent its death-activating 
function. Recently, mutations in the human grim-19 
coding region were reported in Hürthle cell thyroid 
carcinomas (Maximo et al. 2005). To gain better 
understanding of molecular changes that appear in 
primary renal cell carcinoma (RCC), we compared 
the proteomes of normal kidney and RCC 
(Alchanati et al. 2006). Unlike prostate tumors, 
chromosome 19 anomalies are extremely rare in 
RCC. Results from this study revealed that: 1) 93% 
of RCCs lost GRIM-19 expression, and in the 
remainder only weak expression was noted, (2) 
Loss of GRIM-19 appears to be a characteristic of 
clear cell type RCCs and (3) a low frequency loss 
of GRIM-19 also occurs in prostatic and transition 
cell carcinomas. In most cases, tumor-derived 
GRIM-19 mRNA seems to harbor no mutations, 
except for a conservative substitution in one case 
(Alchanati et al. 2006). In those cases where com-
plete loss of mRNA occurred, no gross deletions 
in the GRIM-19 gene were observed as analyzed 
by genomic PCR of tumor and normal DNAs 
(Nallar and Kalvakolanu, unpublished observations). 
Methylation or/and loss of transcription factor 
Figure 2. Cellular roles of GRIM-19. GRIM-19 appears to have more functions than previously envisaged: 1) It targets growth-promoting 
proteins, STAT3 and Src, to achieve growth control; 2) It augments the activity of HtrA2 to cleave XIAP; 3) In conjunction with NOD2 it par-
ticipates in innate immune responses. GRIM-19 can perform these functions only when it is present in more than one intra-cellular compart-
ment. For example, nuclear and cytosolic GRIM-19 can effectively block STAT3 and Src, respectively. GRIM-19 overexpression effectively 
blocks cell motility by decreasing tubulin polymerization. Upon IFN/RA stimulation, the de-novo synthesized GRIM-19 participates in growth 
control in conjunction with other proteins. Requirement of GRIM-19 for complex-I assembly and stability vis-à-vis ATP generation, is one of 
its reported functions. Red colored-lines and arrows represent GRIM-19-dependent inhibitory and stimulatory pathways, respectively. Blue 
colored lines and arrows represent STAT3-dependent inhibitory and stimulatory pathways, respectively. Green arrows represent novel 
GRIM-19 inductive and functional pathways. P in green and pink colored circles indicate phosphorylations at Serine 727 and tyrosine 705 
residues, respectively.76
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engagement with the promoter could be the reasons 
for loss of expression.
We have also proﬁ  led a few oral squamous 
cell carcinoma (SCC) samples where the levels 
of GRIM-19 was not significantly different, 
except for one sample that had a complete loss 
of expression, but STAT3 levels were signiﬁ  -
cantly higher in the tumors of matched samples 
(Nallar and Kalvakolanu, unpublished). An ear-
lier study by (Nindl et al. 2006) on cutaneous 
SCC, by microarray expression proﬁ  ling, con-
cluded no signiﬁ  cant differences with respect to 
GRIM-19 levels. A recent study by (Gong et al. 
2007) on colorectal carcinomas reported higher 
levels of STAT3 and lower levels of GRIM-19 
in matched samples. No mutation was detected 
in GRIM-19 gene in the 23 specimens studied in 
this study.
Conclusions
IFNs have been on the forefront in basic and 
clinical investigations and have emerged as a 
potent therapeutic agent; however, the least under-
stood mechanism of IFN action is regulation of 
cell growth control. In this review we described 
the actions of an IFN/RA-induced gene, GRIM-19, 
in growth control. Although the GRIMs were 
identiﬁ  ed as IFN/RA-induced cell death regulators 
prima facie, they may participate in growth- 
regulatory processes controlled by other ligands 
and in other physiologic processes in normal cells 
(Table 1). Indeed, recent studies have shown a) 
GRIM-19 to be a part of the membrane module of 
complex-I, that is added during the pre-ﬁ  nal stage 
of complex-I assembly (Vogel et al. 2007) and b) 
GRIM-19 is essential for Ca
++ homeostasis during 
embryogenesis (Chen et al. 2007).
Figure 3. Function of GRIM-19 in steady-state. Coordinated synthesis cum assembly of mitochondrial complex-I has been well-characterized. 
In addition to the structural and functional proteins in complex-I, distantly-related proteins like GRIM-19 and AIF are required for proper 
complex-I formation.  Homozygous deletion of grim19 resulted in embryonic lethality in mice which may be a result of decreased complex-I 
levels in the developing embryo. M-coded—mitochondrial DNA-encoded, N-coded—Nuclear DNA-encoded.77
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The maintenance of genomic integrity is crucial 
for preventing tumor development. Cell cycle 
checkpoints play a crucial role in these processes. 
The dominant G1 and G1-S checkpoint responses 
are routed through p53 and pRb, which are most 
commonly deregulated in human cancers (Bartek 
et al. 1997; Kastan and Lim, 2000; Sherr and 
McCormick, 2002). The transcription factors E2F-
1 and c-myc, targets of unphosphorylated STAT3, 
regulate the expression of genes associated with 
cell-cycle progression Cyclin D1 and Cyclin E that 
control G1-S transition (Lee et al. 2000; Ohtani 
et al. 1995). The ability of GRIM-19 to attenuate 
STAT3 responses adds a new dimension to this 
checkpoint. Like p53 and pRb, human tumors show 
loss of expression or/and mutations in GRIM-19. 
In this regard, GRIM-19 may now be classiﬁ  ed as 
a new tumor suppressor, given a loss of its 
expression in tumors and accumulation of 
mutations in its gene in certain tumors. In S-phase, 
GRIM-19 blocks GW112, whose function is not 
known at present. The G2 and G2-M checkpoint is 
controlled by the activity of Cyclin B1/CDK1 
kinase (Lukas et al. 1999; Onishi et al. 1997). 
Incidentally, Cyclin B1 also happens to be a 
STAT3-responsive gene that can be controlled by 
GRIM-19. Thus GRIM-19 may act as a ‘gentle 
brake’ throughout the cell-cycle in a normal cells 
emphasizing its role as a wide-spectrum growth 
controller i.e. in the absence of any stress-like 
situation(s). However, viruses have evolved 
strategies to nullify the growth-controlling function 
of GRIM-19 (Fig. 1). Having said this, cooperativity 
among GRIMs is required for full-blown apoptosis 
upon IFN/RA treatment that is distinct from known 
pathways of apoptosis and the GRIM machinery 
even causes cell death in p53 and Caspase 
3-deﬁ  cient cells (Kalvakolanu, 2004). Unlike most 
apoptosis-inducing proteins, whose cellular 
localizations are delineated, GRIM-19 appears to 
ﬂ  oat inside the cell (Fig. 2) and perform its diverse 
house-keeping functions viz., apoptosis, growth-
control, innate immunity, complex-I assembly etc. 
The most difﬁ  cult of GRIM-19 function to study 
is complex-I assembly as 45-plus gene products 
are involved in the process and deﬁ  ciency of many 
related gene products manifest similarly i.e. 
defective complex-I (Fig. 3). Does the sub-cellular 
localization of GRIM-19 determine its steady-state 
function and apoptotic behavior? The stress factors 
that activate the apoptotic behavior of GRIM-19 
are currently being investigated.
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